Methylene Blue — Non-Peptide
A non-peptide redox agent with an FDA-approved intravenous product for acquired methemoglobinemia; wellness and cognitive uses are not approved indications.
OVERVIEW
Methylene blue is a redox-active compound, not a peptide. ProvayBlue is FDA-approved for acquired methemoglobinemia. Mitochondrial, cognitive, and general wellness uses discussed in integrative settings are off-label and are not established FDA-approved indications.
Proposed Mechanisms
• Oxidation-reduction activity • Electron-transfer effects • Mitochondrial mechanisms are under study for non-approved uses
Potential Applications
• FDA-approved: acquired methemoglobinemia • Investigational/off-label: cognitive and mitochondrial wellness applications
Pharmacokinetics
Formulation-specific. The source draft cited approximately 70% oral bioavailability and a 5–24 hour half-life; those figures do not establish efficacy or safety for wellness use.
Dosing
Approved IV dosing is product- and indication-specific; the ProvayBlue label describes 1 mg/kg intravenously over 5–30 minutes for acquired methemoglobinemia. The source draft's 5–20 mg oral wellness dosing is not FDA-approved.
Monitoring
• Methemoglobin and vital signs for the approved indication • Medication-interaction review • Hemolysis risk • Neurologic and serotonergic symptoms
Side Effects
Important labeled risks include serious or fatal serotonin syndrome with serotonergic drugs, hypersensitivity, hemolytic anemia, and interference with monitoring devices or laboratory tests.
Contraindications
• Severe hypersensitivity to methylene blue • Glucose-6-phosphate dehydrogenase deficiency • Avoid concomitant serotonergic drugs per boxed warning • Pregnancy requires product-label and clinician review
FDA/Investigational Status
FDA-approved only for the labeled ProvayBlue indication. Cognitive, mitochondrial, anti-aging, and general wellness uses are off-label and should not be marketed as FDA-approved.
Disclaimer/Notes
Label clearly as non-peptide. Do not omit the boxed warning or G6PD-related contraindication when presenting educational material.
Clinical Review Status
Clinical + legal review required before publishing